Advertisement

Gene Therapy for Fibroproliferative Phase Ards

  • Paul N. Reynolds
  • Mitchell A. Olman
Chapter

Abstract

Following an acute injury to the lung, restoration of the normal alveolar architecture and function is the ideal outcome. Unfortunately, following a myriad of endovascular or inhaled toxins, a series of temporally and spatially overlapping injury and repair events all too often result in a dysfunctional fibrotic lung. The fibroproliferative phase of acute lung injury is characterized by progressive accumulation of interstitial and alveolar myofibroblasts and matrix leading to impaired gas exchange and severely reduced lung compliance. The critical feature of this late stage (1–4 weeks after injury) of the injury/repair continuum is the disruption of normal alveolar architecture. For normal lung function to return, both the liquid and protein barrier function and the diffusion properties of the alveolar-capillary structures must be restored. The requisite temporal and spatial coordination of alveolar proteolysis, cell proliferation, apoptosis, angiogenesis, matrix synthesis and epithelial cell re-population provide ample and complementary biological pathways for targeting gene therapy (1, 2, 3, 4, 5, 6). This chapter will review the alveolar architectural and biochemical abnormalities that occur within the first few weeks of a severe lung injury and discuss potential targets, successes and delivery modes for gene therapy designed to reduce the fibroproliferative response.

Keywords

Cystic Fibrosis Gene Therapy Lung Injury Plasminogen Activator Acute Lung Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Literature Cited

  1. 1.
    Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol. 1999;162:5511–5518.PubMedGoogle Scholar
  2. 2.
    Marinelli WA, Henke CA, Harmon KR, Hertz MI, Bitterman PB. Mechanisms of alveolar fibrosis after acute lung injury. Clin Chest Med. 1990;11:657–659.PubMedGoogle Scholar
  3. 3.
    Olman M, Mackman N, Gladson C, Moser K, Loskutoff D. Changes in procoagulant and fibrinolytic gene expression during bleomycin induced lung injury in the mouse. J Clin Invest. 1995;96:1621–1630.PubMedCrossRefGoogle Scholar
  4. 4.
    Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol. 1999;163:5686–5692.PubMedGoogle Scholar
  5. 5.
    Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest. 1999;104:13–19.PubMedCrossRefGoogle Scholar
  6. 6.
    Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Molec Biol. 1997;16:91–101.Google Scholar
  7. 7.
    Svee K, White J, Vaillant P, Jessurun J, Roongta U, Krumwiede M, Johnson D, Henke C. Acute lung injury fibroblast migration and invasion of a fibrin matrix is mediated by CD44. J Clin Invest. 1996;98:1713–1727.PubMedCrossRefGoogle Scholar
  8. 8.
    Klagsbrun M, Shing Y: Heparin affinity of anionic and cationic capillary endothelial cell growth factors: Analysis of hypothalamus-derived growth factors and fibroblast growth factors. Proc Natl Acad Sci USA. 1985;82:805–809.PubMedCrossRefGoogle Scholar
  9. 9.
    Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE, Altieri DC. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 1993;73:1423–1434.PubMedCrossRefGoogle Scholar
  10. 10.
    Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, Altieri DC. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc.Natl.Acad.Sci.USA. 1995;92:1505–1509.PubMedCrossRefGoogle Scholar
  11. 11.
    Horton MR, McKee CM, Bao C, Liao F, Farber JM, Hodge-DuFour J, Pure E, Oliver BL, Wright TM, Noble PW. Hyaluronan fragments synergize with interfoeron-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages. J Biol Chem. 1998;273:35088–35094.PubMedCrossRefGoogle Scholar
  12. 12.
    Skogen WF, Senior RM, Griffin GL, Wilner GD. Fibrinogen-derived peptide B β1–42 is a multidomained neutrophil chemoattractant. Blood. 1988;71:145–149.Google Scholar
  13. 13.
    Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response: studies with human fibrinopeptide B.J Clin Invest. 1986;77:1014–1019.PubMedCrossRefGoogle Scholar
  14. 14.
    Sahni A, Sporn LA, Francis CW. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem. 1999;274:14936–14941.PubMedCrossRefGoogle Scholar
  15. 15.
    Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Garcia M: Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J Cell Phys 1993;155:595–605Google Scholar
  16. 16.
    Saarialho-Kere UK, Kovacs SO, Pentland AP, Olerud JE, Welgus HG, Parks WC. Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest. 1993;92:2858–2866.PubMedCrossRefGoogle Scholar
  17. 17.
    Bachofen A, Weibel ER: Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis. 1977;116:589–615.Google Scholar
  18. 18.
    Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Amer J Path. 1987;126:171–182.PubMedGoogle Scholar
  19. 19.
    Kuhn C, III, Boldt J, King TE, Jr., Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140:1693–1703.PubMedCrossRefGoogle Scholar
  20. 20.
    Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med. 1997;155:1187–1205.PubMedGoogle Scholar
  21. 21.
    Martin TR. Lung cytokines and ARDS: Roger S. Mitchell Lecture. Chest 1999;116:2S–8S.PubMedCrossRefGoogle Scholar
  22. 22.
    Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, Martin TR: Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:602–611.PubMedGoogle Scholar
  23. 23.
    Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, Greenheck JR, Chen B, Bitterman PB Acute lung injury. Pathogenesis of intraalveolar fibrosis. J Clin Invest. 1991;88:663–673.PubMedCrossRefGoogle Scholar
  24. 24.
    Raghu G, Striker LJ, Hudson LD, Striker GE Extracellular matrix in normal and fibrotic human lungs. Am Rev Resp Dis. 1985;131:281–289.PubMedGoogle Scholar
  25. 25.
    Clark JG, Milberg JA, Steinberg KP, Hudson LD. Type III procollagen peptide in the adult respiratory distress syndrome. Annals Internal Med. 1995;122:17–23.Google Scholar
  26. 26.
    Chesnutt AN, Matthay MA, Tibayan FA, Clark JG. Early detection of type III procollagen peptide in acute lung injury. Am J Respir Crit Care Med. 1997;156:840–845.PubMedGoogle Scholar
  27. 27.
    Doerschuk CM, Mizgerd JP, Kubo H, Qin L, Kumasaka T. Adhesion molecules and cellular biomechanical changes in acute lung injury: Giles F. Filley Lecture. Chest. 1999;116:37S–43S.PubMedCrossRefGoogle Scholar
  28. 28.
    Piguet PF, Rosen H, Vesin C, Grau GE. Effective treatment of the pulmonary fibrosis elicted in mice by bleomycin or silica with anti-CD-11 antibodies. Am Rev Resp Dis. 1993;147:435–441.PubMedGoogle Scholar
  29. 29.
    Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739–2745.PubMedCrossRefGoogle Scholar
  30. 30.
    Simmons WL, Rivera KE, Curiel DT, Williams W, Olman MA. Adenovirally-mediated gene transfer of functional human tissue-type plasminogen activator to murine lungs. Am J Respir Cell Mol Biol. 1998;18:307–314.PubMedGoogle Scholar
  31. 31.
    Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA. 1994;91:215–219.PubMedCrossRefGoogle Scholar
  32. 32.
    Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB. Purification and initial characterization of a type-transforming growth factor from human placenta. Proc Natl AcadSci.USA 1983;3676–3680.Google Scholar
  33. 33.
    Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax. 1993;48:959–966.PubMedCrossRefGoogle Scholar
  34. 34.
    Roberts CJ, Birkenmeier TM, McQuillan JJ, Akiyama SK, Yamada SS, Chen W, Yamad KM, McDonald JA. Transforming growth factor B stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J Biol Chem. 1988;263:4586–4592.PubMedGoogle Scholar
  35. 35.
    Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. New Eng J Med. 1994;331:1286–1292.PubMedCrossRefGoogle Scholar
  36. 36.
    Santana A, Saxena B, Noble NA, Gold LI, Marshall BC. Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1995; 13:34–44. PubMedGoogle Scholar
  37. 37.
    Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor (31 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA. 1991;88:6642–6646.PubMedCrossRefGoogle Scholar
  38. 38.
    Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J. 1994;7:515–518.PubMedCrossRefGoogle Scholar
  39. 39.
    Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170:655–663.PubMedCrossRefGoogle Scholar
  40. 40.
    Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, Piguet PF, Vassalli P. Expression of a tumor necrosis factor-a transgene in murine lung causes lymphocytic and fibrosing alveolitis. J Clin Invest. 1995;96:250–259.PubMedCrossRefGoogle Scholar
  41. 41.
    Ortiz LA, Lasky J, Hamilton RF, Jr., Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res. 1998;24:721–743.PubMedCrossRefGoogle Scholar
  42. 42.
    McCoy RD, Eitzman, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or over-express the murine plasminogen activator inhibitor-1 gene. Am J Resp Crit Care Med. 1995;151:A51.Google Scholar
  43. 43.
    Barazzone C, Belin D, Piguet PF, Vassalli JD, Sappinno AP. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest. 1996;98:2666–2673.PubMedCrossRefGoogle Scholar
  44. 44.
    Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dano K. Imparted wound healing in mice with a disrupted plasminogen gene. Nature Med. 1996;2:287–292.PubMedCrossRefGoogle Scholar
  45. 45.
    Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MS, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 1996;87:709–719.PubMedCrossRefGoogle Scholar
  46. 46.
    Olman MA, Simmons WL, Pollman DJ, Loftis AY, Bini A, Miller EJ, Fuller GM, Rivera K. Polymerization of fibrinogen in murine bleomycin-induced lung injury. Am J Physiol. 1996;271:L519–L526.PubMedGoogle Scholar
  47. 47.
    Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Cur Opin Cell Bio. 1997;9:714–724.CrossRefGoogle Scholar
  48. 48.
    Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest. 1999;104:5–11.PubMedCrossRefGoogle Scholar
  49. 49.
    Tran PL, Weinbach J, Opolon P, Linares-Cruz G, Reynes JP, Gregoire A, Kremer E, Durand H, Perricaudet M. Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene. J Clin Invest. 1997;99:608–17.PubMedCrossRefGoogle Scholar
  50. 50.
    Hattori N, Sisson TH, Xu Y, Simon RH. Upregulation of fibrinolysis by adenovirus-mediated transfer of urokinase-type plasminogen activator genes to lung cells in vitro and in vivo. Hum Gene Ther. 1999;10:215–22.PubMedCrossRefGoogle Scholar
  51. 51.
    Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther. 1999;10:2315–23.PubMedCrossRefGoogle Scholar
  52. 52.
    Simmons WL, Rivera KE, Curiel DT, Williams WF, Olman MA. Adenovirally mediated gene transfer of functional human tissue-type plasminogen activator to murine lungs. Am J Respir Cell Mol Biol. 1998;18:307–14.PubMedGoogle Scholar
  53. 53.
    Albelda SM, Wiewrodt R, Zuckerman JB. Gene therapy for lung disease: hype or hope? Ann Intern Med. 2000;132:649–60.PubMedGoogle Scholar
  54. 54.
    Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, Accart N, Layani MP, Aymard M, Bernon H, Bienvenu J, Courtney M, Doring G, Gilly B, Gilly R, Lamy D, Levrey H, Morel Y, Paulin C, Perraud F, Rodillon L, Sene C, So S, Touraine-Moulin F, Pavirani A, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther. 1997;8:15–25.PubMedCrossRefGoogle Scholar
  56. 56.
    Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J, Baker C, Goldman MJ, Wilson JM. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999;10:2973–85.PubMedCrossRefGoogle Scholar
  57. 57.
    Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 1993;75:207–16.PubMedCrossRefGoogle Scholar
  58. 58.
    Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther. 1995;6:1487–96.PubMedCrossRefGoogle Scholar
  59. 59.
    Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. NEJM. 1995;333:823–31.PubMedCrossRefGoogle Scholar
  60. 60.
    Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J, Moscicki RA, Richards SM, Standaert TA, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest. 1996;97:1504–11.PubMedCrossRefGoogle Scholar
  61. 61.
    Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Walters RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem. 1999;274:10219–26.PubMedCrossRefGoogle Scholar
  63. 63.
    Parsons DW, Grubb BR, Johnson LG, Boucher RC. Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent. Hum Gene Ther. 1998;9:2661–72.PubMedCrossRefGoogle Scholar
  64. 64.
    Kaplan JM, Pennington SE, St. George JA, Woodworth LA, Fasbender A, Marshall J, Cheng SH, Wadsworth SC, Gregory RJ, Smith AE. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum GeneTher. 1998;9:1469-79.Google Scholar
  65. 65.
    Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest. 1998;102:184–93.PubMedCrossRefGoogle Scholar
  66. 66.
    Weiss DJ, Strandjord TP, Liggitt D, Clark JG. Perflubron enhances adenovirus-mediated gene expression in lungs of transgenic mice with chronic alveolar filling. Hum Gene Ther. 1999;10:2287–93.PubMedCrossRefGoogle Scholar
  67. 67.
    Wickham TJ. Targeting adenovirus. Gene Ther. 2000;7:110–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Drapkin PT, O'Riordan CR, Yi SM, Chiorini JA, Cardella J, Zabner J, Welsh MJ. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest. 2000;105:589–96.PubMedCrossRefGoogle Scholar
  69. 69.
    Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O’Riordan CR. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther. 1999;10:2615–26.PubMedCrossRefGoogle Scholar
  70. 70.
    Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, Gardner P. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998;351:1702–3.PubMedCrossRefGoogle Scholar
  71. 71.
    Walters RW, Duan D, Engelhardt JF, Welsh MJ. Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer to airway epithelia in vitro and in vivo. J Virol. 2000;74:535–40.PubMedCrossRefGoogle Scholar
  72. 72.
    Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab’gamma)2 antibody. Nat Biotechnol. 1999;17:181–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1995;1:39–46.PubMedCrossRefGoogle Scholar
  74. 74.
    Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, Thomson A, MacVinish LJ, Ratcliff R, Bilton D, Lane DJ, Littlewood JM, Webb AK, Middleton PG, Colledge WH, Cuthbert AW, Evans MJ, Higgins CF, Hyde SC. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997;4:199–209.PubMedCrossRefGoogle Scholar
  75. 75.
    Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WA, Moralee S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho LP, Samways JM, Imrie M, Greening AP, Innes JA. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997;4:210–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Scheule RK, St George JA, Bagley RG, Marshall J, Kaplan JM, Akita GY, Wang KX, Lee ER, Harris DJ, Jiang C, Yew NS, Smith AE, Cheng SH. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther. 1997;8:689–707.PubMedCrossRefGoogle Scholar
  77. 77.
    Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J, Scheule RK, Cheng SH. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther. 1999;10:223–34.PubMedCrossRefGoogle Scholar
  78. 78.
    Rodman DM, San H, Simari R, Stephan D, Tanner F, Yang Z, Nabel GJ, Nabel EG. In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am J Respir Cell Molr Biol. 1997;16:640–9.Google Scholar
  79. 79.
    Danilov SM, Muzykantov VR, Martynov AV, Atochina EN, Sakharov I, Trakht IN, Smirnov VN. Lung is the target organ for a monoclonal antibody to angiotensin-converting enzyme. Lab Invest. 1991;64:118–24.PubMedGoogle Scholar
  80. 80.
    Conary JT, Parker RE, Christman BW, Faulks RD, King GA, Meyrick BO, Brigham KL. Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene. J Clin Invest. 1994;93:1834–40.PubMedCrossRefGoogle Scholar
  81. 81.
    Goula D, Becker N, Lemkine GF, Normandie P, Rodrigues J, Mantero S, Levi G, Demeneix BA. Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther. 2000;7:499–504.PubMedCrossRefGoogle Scholar
  82. 82.
    Li S, Tan Y, Viroonchatapan E, Pitt BR, Huang L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am J Physiol. 2000;278:L504–L511.Google Scholar
  83. 83.
    Song YK, Liu F, Liu D. Enhanced gene expression in mouse lung by prolonging the retention time of intravenously injected plasmid DNA. Gene Ther. 1998;5:1531–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Campbell AI, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 1999;21:567–75.PubMedGoogle Scholar
  85. 85.
    Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol. 1997;71:624–9.PubMedGoogle Scholar
  87. 87.
    O’Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10:1349–58.PubMedCrossRefGoogle Scholar
  88. 88.
    Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, Crystal RG. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther. 1997;8:1675–84.PubMedCrossRefGoogle Scholar
  89. 89.
    Otake K, Ennist DL, Harrod K, Trapnell BC. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther. 1998;9:2207–22.PubMedCrossRefGoogle Scholar
  90. 90.
    Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407–11.PubMedCrossRefGoogle Scholar
  91. 91.
    Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D, Wang F, Metzker ML, Savino R, Caskey CT. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA. 2000;97:1002–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Morral N, O’Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA. 1999;96:12816–21.PubMedCrossRefGoogle Scholar
  93. 93.
    Balague C, Zhou J, Dai Y, Alemany R, Josephs SF, Andreason G, Hariharan M, Sethi E, Prokopenko E, Jan HY, Lou YC, Hubert-Leslie D, Ruiz L, Zhang WW. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood. 2000;95:820–8.PubMedGoogle Scholar
  94. 94.
    Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 1998;72:4212–23.PubMedGoogle Scholar
  95. 95.
    Fisher JH, Sheftelyevich V, Ho YS, Fligiel S, McCormack FX, Korfhagen TR, Whitsett JA, Ikegami M. Pulmonary-specific expression of SP-D corrects pulmonary lipid accumulation in SP-D gene-targeted mice. Am J Physiol. 2000;278:L365–73.Google Scholar
  96. 96.
    Morishita K, Johnson DE, Williams LT. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem. 1995;270:27948–53.PubMedCrossRefGoogle Scholar
  97. 97.
    Papi A, Johnston SL. Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors. J Biol Chem. 1999;274:30041–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Paul N. Reynolds
    • 1
  • Mitchell A. Olman
    • 1
  1. 1.University of Alabama at BirminghamBirminghamUSA

Personalised recommendations